Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention

• Published in: Cancers Vol. 13; no. 4; p. 641
• Main Authors: Dobaño-López, Cèlia, Araujo-Ayala, Ferran, Serrat, Neus, Valero, Juan G, Pérez-Galán, Patricia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.02.2021; MDPI
• Subjects: Apoptosis; B-cell lymphoma; Biopsy; Cell growth; Clinical trials; Cytokines; Cytometry; Dendritic cells; follicular lymphoma; Gene expression; Genomes; Genotype & phenotype; immunotherapy; Lymphocytes; Lymphoma; Medical prognosis; microenvironment; Microenvironments; Mutation; Patients; Phenotypes; Proteins; Recruitment; Review; Ribonucleic acid; RNA; Tumors; microenvironment; follicular lymphoma; immunotherapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13040641

Follicular Lymphoma (FL), the most common indolent non-Hodgkin's B cell lymphoma, is a paradigm of the immune microenvironment's contribution to disease onset, progression, and heterogeneity. Over the last few years, state-of-the-art technologies, including whole-exome sequencing, single-cell RNA sequencing, and mass cytometry, have precisely dissected the specific cellular phenotypes present in the FL microenvironment network and their role in the disease. In this already complex picture, the presence of recurring mutations, including and , have a prominent contributory role, with some of them finely tuning this exquisite dependence of FL on its microenvironment. This precise characterization of the enemy (FL) and its allies (microenvironment) has paved the way for the development of novel therapies aimed at dismantling this contact network, weakening tumor cell support, and reactivating the host's immune response against the tumor. In this review, we will describe the main microenvironment actors, together with the current and future therapeutic approaches targeting them.